Adintrevimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Adintrevimab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Adintrevimab can convert its Monoclonal antibody profile and SARS-CoV-2 S protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Adintrevimab (query alias: Adintrevimab) |
|---|---|
| Modality / target | Monoclonal antibody; SARS-CoV-2 S protein; SARS-CoV-2 S protein modulators |
| Highest global status | Phase 3 |
| Originator | Invivyd, Inc. |
| Active developers | Invivyd, Inc. |
The MCP disease footprint includes COVID-19. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04859517 | Phase 2/3 | Terminated | 2582 | Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP) |
| CTRI/2021/12/038474 | Phase 2/3 | Open to Recruitment | 1084 | Not disclosed |
| NCT04805671 | Phase 2/3 | Terminated | 399 | Incidence of COVID-19 Related Hospitalizations or All-cause Death |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2/3 Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
Phase 2/3; n=2582; evaluation: not stated. Reported fields: Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP): Risk Difference (RD) = -5.0(95% CI, -8.87 to -1.08), P-Value = 0.0123; Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP) = 3 Participants ; Percentage of Participants With RT-PCR Confirmed Symptomatic COVID-19 (PEP): Risk Difference (RD) = -5.0(95% CI, -8.87 to -1.08), P-Value = 0.0123
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants With Mild or Moderate COVID-19 (STAMP)
Phase 2/3; n=399; evaluation: not stated. Reported fields: Incidence of COVID-19 Related Hospitalizations or All-cause Death: Risk Difference (RD) = -8.7(95% CI, -14.71 to -2.67), P-Value = 0.0047; Incidence of COVID-19 Related Hospitalizations or All-cause Death = 8 Participants ; Incidence of COVID-19 Related Hospitalizations or All-cause Death: Risk Difference (RD) = -8.7(95% CI, -14.71 to -2.67), P-Value = 0.0047
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Phase 2/3; n=2582; evaluation: Positive. Reported fields: Incidence(RT-PCR-confirmed symptomatic COVID-19) = 5.5 % ; Incidence(RT-PCR-confirmed symptomatic COVID-19) = 6.8 % ; Incidence(RT-PCR-confirmed symptomatic COVID-19) = 1.7 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Adintrevimab addresses COVID-19. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-07-26 | Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19 | Phase 2/3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
